Scalper1 News
Biotech Intercept Pharmaceuticals (ICPT) announced Tuesday that it had hammered out a design for a phase three trial of its nonalcoholic steatohepatitis (NASH) treatment, but the stock sold off as the time frame looked longer than many investors expected. There’s no current treatment for NASH, a slow-acting disease in which fat buildup around the liver causes progressive scarring, which is why there was no previous model of a large clinical trial Scalper1 News
Scalper1 News